Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3. Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:CLVS
- CUSIP: 18946410
- Web: www.clovisoncology.com
Capitalization:- Market Cap: $3.67 billion
- Outstanding Shares: 48,879,000
Average Prices:- 50 Day Moving Avg: $73.35
- 200 Day Moving Avg: $69.15
- 52 Week Range: $25.50 - $99.45
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -30.50
- P/E Growth: 0.12
Sales & Book Value:- Annual Revenue: $21.74 million
- Price / Sales: 168.72
- Book Value: $7.04 per share
- Price / Book: 10.66
Profitability:- EBIDTA: ($242,160,000.00)
- Return on Equity: -177.30%
- Return on Assets: -47.13%
Debt:- Debt-to-Equity Ratio: 0.82%
- Current Ratio: 3.26%
- Quick Ratio: 3.23%
Misc:- Average Volume: 1.82 million shs.
- Beta: 1.58
- Short Ratio: 4.95
Frequently Asked Questions for Clovis Oncology (NASDAQ:CLVS)
What is Clovis Oncology's stock symbol?
Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."
How were Clovis Oncology's earnings last quarter?
Clovis Oncology, Inc. (NASDAQ:CLVS) released its quarterly earnings results on Wednesday, August, 2nd. The company reported ($1.29) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.27) by $0.02. The company had revenue of $14.62 million for the quarter, compared to the consensus estimate of $13.07 million. Clovis Oncology's quarterly revenue was down 32.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($2.07) earnings per share. View Clovis Oncology's Earnings History.
When will Clovis Oncology make its next earnings announcement?
Where is Clovis Oncology's stock going? Where will Clovis Oncology's stock price be in 2017?
17 brokers have issued 1 year target prices for Clovis Oncology's stock. Their forecasts range from $38.00 to $125.00. On average, they expect Clovis Oncology's stock price to reach $83.40 in the next twelve months. View Analyst Ratings for Clovis Oncology.
What are analysts saying about Clovis Oncology stock?
Here are some recent quotes from research analysts about Clovis Oncology stock:
- 1. Cann analysts commented, "In a presentation on Saturday at the 2017 European Society for Medical Oncology (ESMO) Congress, Clovis Oncology released additional details from the results of the phase III ARIEL3 study of Rucraca. In addition to PFS results, Clovis presented response rate data from an exploratory analysis of investigator-assessed ORR for patients with measurable disease at baseline. These response rate data are consistent with the previously released PFS data." (9/11/2017)
- 2. According to Zacks Investment Research, "Clovis got a huge boost with the FDA granting accelerated approval to its advanced ovarian cancer treatment, Rubraca in Dec 2016. Rubraca has bright prospects, given the tremendous demand for PARP inhibitors. Successful commercialization will significantly boost Clovis’ sales. Rubraca is also under review in the EU for a comparable indication. Several studies on Rubraca, targeting different types of ovarian cancer patients, are currently underway. Promising progression-free survival and safety results from the ARIEL3 maintenance study is expected to help expand Rubraca’s label. However, with just one approved product in the portfolio, Clovis is heavily dependent on Rubraca for growth, which concerns us. Rubraca is also set to face intense competition from currently marketed PARP inhibitors. Loss estimates have widened lately ahead of the Q2 results. Clovis has a mixed earnings surprise record in the recent quarters." (7/13/2017)
- 3. Goldman Sachs Group, Inc. (The) analysts commented, "AZN (covered by Keyur Parekh) presented data from a Ph3 SOLO-2 maintenance ovarian cancer trial of Lynparza (PARP inhibitor) on March 14 at the SGO conference, which we believe has implications for CLVS (lead marketed drug Rubraca is also a PARP). CLVS, AZN and TSRO (not covered) all have PARP inhibitors that they are evaluating for use in the maintenance treatment of ovarian cancer." (3/15/2017)
- 4. Stifel Nicolaus analysts commented, "This price assumes about a 40% market share for rucaparib throughout addressable ovarian cancer (OC). However, in deriving this target, we include sales in the maintenance setting for ovarian cancer with a weighting of 75% (some risk remains to ARIEL3) and note that full weighing of this unapproved usage would suggest a fair value of about $104. Furthermore, inclusion of sales in mCRPC, which we consider highly promising but where large trials are just starting, suggests a fair value for Clovis shares of about $182. We consider most of the ongoing trials for rucaparib to be relatively low risk, but with several other players also competing for each indication we believe a takeout price of about 50% of our best case scenario makes sense." (1/23/2017)
Who are some of Clovis Oncology's key competitors?
Some companies that are related to Clovis Oncology include TESARO (TSRO), Bioverativ (BIVV), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), AveXis (AVXS), Sarepta Therapeutics (SRPT), Axovant Sciences Ltd (AXON), GW Pharmaceuticals PLC (GWPH), Spark Therapeutics (ONCE), Loxo Oncology (LOXO), China Biologic Products (CBPO), Prothena Corporation PLC (PRTA), Intercept Pharmaceuticals (ICPT), Halozyme Therapeutics (HALO) and Ultragenyx Pharmaceutical (RARE).
Who are Clovis Oncology's key executives?
Clovis Oncology's management team includes the folowing people:
- M. James E. Barrett Ph.D., Independent Chairman of the Board
- Patrick J. Mahaffy, President, Chief Executive Officer, Director
- Daniel W. Muehl, Senior Vice President of Finance, Principal Accounting Officer and Principal Financial Officer
- Gillian C. Ivers-Read, Executive Vice President - Technical Operations, Chief Regulatory Officer
- Lindsey Rolfe BSc, MB ChB, MRCP, F, Executive Vice President - Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer
- C. Dale Hooks, Senior Vice President, Chief Commercial Officer
- Brian G. Atwood, Independent Director
- James C. Blair Ph.D., Independent Director
- Keith T. Flaherty M.D., Independent Director
- Ginger L. Graham, Independent Director
Who owns Clovis Oncology stock?
Clovis Oncology's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.11%), Palo Alto Investors LLC (6.81%), PointState Capital LP (4.08%), State Street Corp (3.98%), FMR LLC (3.88%) and Franklin Resources Inc. (3.73%). Company insiders that own Clovis Oncology stock include Erle T Mast, Gillian C Ivers-Read, James C Blair and Lindsey Rolfe. View Institutional Ownership Trends for Clovis Oncology.
Who sold Clovis Oncology stock? Who is selling Clovis Oncology stock?
Clovis Oncology's stock was sold by a variety of institutional investors in the last quarter, including GAM Holding AG, Palo Alto Investors LLC, Versant Venture Management LLC, C WorldWide Group Holding A S, FMR LLC, Westfield Capital Management Co. LP, PDT Partners LLC and Blue Jay Capital Management LLC. Company insiders that have sold Clovis Oncology stock in the last year include Gillian C Ivers-Read and James C Blair. View Insider Buying and Selling for Clovis Oncology.
Who bought Clovis Oncology stock? Who is buying Clovis Oncology stock?
Clovis Oncology's stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Franklin Resources Inc., Eagle Asset Management Inc., Farallon Capital Management LLC, Fred Alger Management Inc., Macquarie Group Ltd., Vanguard Group Inc. and Samlyn Capital LLC. View Insider Buying and Selling for Clovis Oncology.
How do I buy Clovis Oncology stock?
Shares of Clovis Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clovis Oncology's stock price today?
One share of Clovis Oncology stock can currently be purchased for approximately $75.04.
MarketBeat Community Rating for Clovis Oncology (NASDAQ CLVS)MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Clovis Oncology (NASDAQ:CLVS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 7 Hold Ratings, 10 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.59) |
| Consensus Price Target: | $83.40 (11.14% upside) |
Analysts' Ratings History for Clovis Oncology (NASDAQ:CLVS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/18/2017 | Leerink Swann | Reiterated Rating | Buy | $107.00 | Low |  |
| 9/14/2017 | Royal Bank Of Canada | Initiated Coverage | Sector Perform | $81.00 | Low | |
| 9/11/2017 | Oppenheimer Holdings, Inc. | Reiterated Rating | Hold | | Low | |
| 9/11/2017 | Cann | Reiterated Rating | Hold | | Low | |
| 8/18/2017 | J P Morgan Chase & Co | Reiterated Rating | Buy | | Medium | |
| 8/16/2017 | Evercore ISI | Initiated Coverage | In -> In-Line | $73.00 | High | |
| 8/10/2017 | Morgan Stanley | Reiterated Rating | Overweight | $93.00 | Medium | |
| 8/3/2017 | Bank of America Corporation | Reiterated Rating | Buy | | Low | |
| 7/18/2017 | Credit Suisse Group | Set Price Target | Buy | $107.00 | Low | |
| 7/7/2017 | Gabelli | Initiated Coverage | Buy | $125.00 | High | |
| 6/22/2017 | SunTrust Banks, Inc. | Reiterated Rating | Buy | | Low | |
| 6/20/2017 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Neutral | $67.00 -> $90.00 | High | |
| 6/20/2017 | Janney Montgomery Scott | Upgrade | Neutral -> Buy | | Medium | |
| 6/19/2017 | Stifel Nicolaus | Boost Price Target | Buy | $86.00 -> $125.00 | High | |
| 6/19/2017 | Chardan Capital | Upgrade | Sell -> Neutral | $36.00 -> $50.00 | High | |
| 3/28/2017 | Piper Jaffray Companies | Set Price Target | Buy | $77.00 | Low | |
| 12/21/2016 | WallachBeth Capital | Boost Price Target | Hold | $22.00 -> $49.00 | N/A | |
| 8/24/2016 | Mizuho | Boost Price Target | Neutral | $15.00 -> $23.00 | N/A | |
(Data available from 9/20/2015 forward)
Earnings History for Clovis Oncology (NASDAQ:CLVS)Earnings History by Quarter for Clovis Oncology (NASDAQ CLVS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/1/2017 | | ($1.18) | | | | | N/A | |
| 8/2/2017 | Q2 2017 | ($1.27) | ($1.29) | $13.07 million | $14.62 million | View | Listen | |
| 5/3/2017 | Q1 2017 | ($1.43) | ($1.33) | $6.04 million | $7.05 million | View | Listen | |
| 2/22/2017 | Q416 | ($1.65) | ($1.83) | | $0.08 million | View | Listen | |
| 11/3/2016 | Q316 | ($1.95) | ($1.70) | | | View | Listen | |
| 8/8/2016 | Q216 | ($2.13) | ($2.07) | | | View | Listen | |
| 5/5/2016 | Q116 | ($2.39) | ($2.17) | | | View | Listen | |
| 2/25/2016 | Q415 | ($2.39) | ($2.23) | | | View | Listen | |
| 11/5/2015 | Q315 | ($2.07) | ($2.62) | | | View | Listen | |
| 8/6/2015 | Q215 | ($2.11) | ($2.10) | $1.17 million | | View | Listen | |
| 5/6/2015 | Q115 | ($1.78) | ($1.86) | $13.60 million | | View | Listen | |
| 2/25/2015 | Q414 | ($1.41) | ($1.62) | | | View | Listen | |
| 11/6/2014 | Q314 | ($1.03) | ($1.17) | | | View | Listen | |
| 8/7/2014 | Q214 | ($0.93) | ($1.03) | | $13.60 million | View | Listen | |
| 5/8/2014 | Q114 | ($0.85) | ($0.91) | | $13.60 million | View | Listen | |
| 2/27/2014 | Q4 | ($0.78) | ($0.92) | | | View | Listen | |
| 10/31/2013 | Q313 | ($0.68) | ($0.68) | | | View | Listen | |
| 8/1/2013 | Q2 2013 | ($0.65) | ($0.72) | | | View | Listen | |
| 5/7/2013 | Q1 2013 | ($0.60) | ($0.60) | | | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Clovis Oncology (NASDAQ:CLVS)2017 EPS Consensus Estimate: ($4.97)
2018 EPS Consensus Estimate: ($2.67)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($1.53) | ($1.53) | ($1.53) |
| Q2 2017 | 3 | ($1.30) | ($1.18) | ($1.23) |
| Q3 2017 | 3 | ($1.24) | ($1.10) | ($1.15) |
| Q4 2017 | 3 | ($1.12) | ($1.03) | ($1.06) |
| Q1 2018 | 1 | ($0.85) | ($0.85) | ($0.85) |
| Q2 2018 | 1 | ($0.67) | ($0.67) | ($0.67) |
| Q3 2018 | 1 | ($0.64) | ($0.64) | ($0.64) |
| Q4 2018 | 1 | ($0.51) | ($0.51) | ($0.51) |
(Data provided by Zacks Investment Research)
Dividend History for Clovis Oncology (NASDAQ:CLVS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Clovis Oncology (NASDAQ:CLVS)Insider Ownership Percentage: 17.40%
Institutional Ownership Percentage: 99.03%
Insider Trades by Quarter for Clovis Oncology (NASDAQ:CLVS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $69.50 | $208,500.00 | |
| 8/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $70.05 | $210,150.00 | |
| 8/4/2017 | James C Blair | Director | Sell | 18,450 | $78.61 | $1,450,354.50 | |
| 7/17/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $91.56 | $274,680.00 | |
| 6/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $61.82 | $185,460.00 | |
| 5/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $47.39 | $142,170.00 | |
| 4/17/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $56.02 | $168,060.00 | |
| 3/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $66.99 | $200,970.00 | |
| 11/2/2015 | Erle T. Mast | CFO | Sell | 3,000 | $105.56 | $316,680.00 | |
| 10/28/2015 | Lindsey Rolfe | insider | Sell | 4,000 | $98.02 | $392,080.00 | |
| 10/15/2015 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $91.91 | $275,730.00 | |
| 10/5/2015 | Lindsey Rolfe | insider | Sell | 4,000 | $93.04 | $372,160.00 | |
| 10/1/2015 | Erle T. Mast | CFO | Sell | 3,000 | $90.22 | $270,660.00 | |
| 9/18/2015 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $112.56 | $337,680.00 | |
| 9/1/2015 | Erle T. Mast | CFO | Sell | 3,000 | $79.51 | $238,530.00 | |
| 7/1/2015 | Erle T Mast | CFO | Sell | 3,000 | $85.70 | $257,100.00 | |
| 6/1/2015 | Erle T Mast | CFO | Sell | 3,000 | $88.78 | $266,340.00 | |
| 5/15/2015 | M James Barrett | Director | Sell | 2,424 | $92.43 | $224,050.32 | |
| 4/1/2015 | Erle T Mast | CFO | Sell | 3,000 | $71.25 | $213,750.00 | |
| 3/9/2015 | Erle T Mast | CFO | Sell | 9,000 | $78.84 | $709,560.00 | |
| 3/5/2015 | James C Blair | Director | Sell | 8,528 | $77.70 | $662,625.60 | |
| 1/16/2015 | Steven L Hoerter | Insider | Sell | 10,000 | $67.00 | $670,000.00 | |
| 12/11/2013 | Erle Mast | CFO | Sell | 50,000 | $52.78 | $2,639,000.00 | |
| 12/5/2013 | Thorlef Spickschen | Director | Sell | 9,000 | $56.10 | $504,900.00 | |
| 6/5/2013 | Andrew R Allen | Insider | Sell | 22,594 | $68.54 | $1,548,592.76 | |
| 6/4/2013 | M James Barrett | Director | Sell | 2,483 | $70.80 | $175,796.40 | |
| 6/4/2013 | Parters Vii L P Domain | Major Shareholder | Sell | 159,192 | $64.58 | $10,280,619.36 | |
| 6/4/2013 | Steven L Hoerter | Insider | Sell | 10,000 | $73.06 | $730,600.00 | |
| 3/6/2013 | Parters Vii L P Domain | Major Shareholder | Sell | 250,000 | $24.59 | $6,147,500.00 | |
| 8/16/2012 | Edward J Mckinley | Director | Buy | 9,701 | $15.50 | $150,365.50 | |
(Data available from 1/1/2013 forward)
Headline Trends for Clovis Oncology (NASDAQ:CLVS)
Latest Headlines for Clovis Oncology (NASDAQ:CLVS)
| Source: |
|
| Date | Headline |
|---|
 | Clovis Oncology, Inc. (CLVS) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 20 at 10:46 AM |
| Analyzing Clovis Oncology (CLVS) and CytomX Therapeutics (CTMX)
www.americanbankingnews.com - September 19 at 6:10 PM |
 | Today's Research Reports on Stocks to Watch: Dimension Therapeutics and Clovis Oncology
finance.yahoo.com - September 19 at 5:17 PM |
| Clovis Oncology (CLVS) in Focus: Stock Moves 10.5% Higher
finance.yahoo.com - September 19 at 5:17 PM |
| Clovis Oncology, Inc. (CLVS) Rating Reiterated by Leerink Swann
www.americanbankingnews.com - September 19 at 2:32 PM |
 | Health Care Sector Update for 09/18/2017: CLVS,LLY,ITUS,AEMD - Nasdaq
www.nasdaq.com - September 19 at 3:28 AM |
| Insider Selling: Clovis Oncology, Inc. (CLVS) Insider Sells 3,000 Shares of Stock
www.americanbankingnews.com - September 18 at 7:44 PM |
 | Clovis Oncology Inc. (CLVS) Has Broken Out Of Today's Range
www.rttnews.com - September 18 at 5:20 PM |
| So Much PARP Inhibitor Deal Hype, So Little Payoff
finance.yahoo.com - September 18 at 5:20 PM |
| Clovis Up 10% On Double Normal Volume
finance.yahoo.com - September 18 at 5:20 PM |
 | Clovis Oncology Higher Off Unconfirmed Takeover Chatter
feeds.benzinga.com - September 18 at 12:34 PM |
| Clovis Oncology, Inc. (CLVS) Now Covered by Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 6:06 PM |
 | Clovis Oncology (CLVS) ARIEL3 Study of Rucaparib Published in The Lancet - StreetInsider.com
www.streetinsider.com - September 13 at 11:32 PM |
| Clovis Oncology’s Rucaparib ARIEL3 Study Data Published in The Lancet
finance.yahoo.com - September 13 at 6:31 PM |
| $20.46 Million in Sales Expected for Clovis Oncology, Inc. (CLVS) This Quarter
www.americanbankingnews.com - September 13 at 3:32 AM |
| Should You Keep Your Portfolio Healthy with Biotech ETFs?
finance.yahoo.com - September 12 at 5:57 PM |
| Clovis Oncology Inc (CLVS): Is the Pullback a Buying Opportunity?
finance.yahoo.com - September 11 at 5:57 PM |
| A Pill Might Control Pancreatic Cancer, Even If It Doesn't Cure It
finance.yahoo.com - September 11 at 5:57 PM |
| Clovis Oncology's (CLVS) Hold Rating Reaffirmed at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - September 11 at 3:50 PM |
| Clovis Oncology, Inc. (CLVS) Stock Rating Reaffirmed by Cann
www.americanbankingnews.com - September 11 at 8:10 AM |
| Clovis Oncology (CLVS) Reports Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment ... - StreetInsider.com
www.streetinsider.com - September 8 at 5:42 PM |
| Clovis Oncology (CLVS) Reports Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment ... - StreetInsider.com
www.streetinsider.com - September 8 at 5:42 PM |
| Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers
finance.yahoo.com - September 8 at 5:42 PM |
| Clovis (CLVS) Down 8.1% Since Earnings Report: Can It Rebound? - Nasdaq
www.nasdaq.com - September 7 at 10:31 PM |
 | Clovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of ... - Business Wire (press release)
www.businesswire.com - September 7 at 10:31 PM |
| Clovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of Rucaparib in Advanced Ovarian Cancer at ESMO 2017
finance.yahoo.com - September 7 at 10:31 PM |
| Clovis (CLVS) Down 8.1% Since Earnings Report: Can It Rebound?
finance.yahoo.com - September 7 at 5:27 PM |
| Why Clovis Oncology Fell 7.1% in August
finance.yahoo.com - September 7 at 5:27 PM |
| Clovis Oncology to Present Comprehensive Dataset from Successful ARIEL3 Clinical Trial Program at 2017 ESMO Congress
finance.yahoo.com - August 30 at 5:16 PM |
| After Gilead's Acquisition Of KITE, Who Gets Gobbled Up Next?
finance.yahoo.com - August 30 at 5:16 PM |
| Clovis Oncology, Inc. (CLVS) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - August 26 at 10:42 AM |
| Here's Why Clovis Stock Is Up Almost 60% So Far in 2017 - Nasdaq
www.nasdaq.com - August 23 at 5:54 PM |
| Here's Why Clovis Stock Is Up Almost 60% So Far in 2017
finance.yahoo.com - August 23 at 5:54 PM |
| Ovarian Cancer Market Still Up For Grabs
finance.yahoo.com - August 18 at 5:21 PM |
| Tesaro: Losing It's Edge?
finance.yahoo.com - August 18 at 5:21 PM |
| Clovis Oncology's (CLVS) Buy Rating Reiterated at J P Morgan Chase & Co
www.americanbankingnews.com - August 18 at 11:22 AM |
| Clovis Oncology, Inc. (CLVS) PT Lowered to $107.00
www.americanbankingnews.com - August 18 at 8:12 AM |
| Clovis Oncology, Inc. – Value Analysis (NASDAQ:CLVS) : August 17, 2017
finance.yahoo.com - August 16 at 10:45 PM |
| Clovis Oncology, Inc. (CLVS) Now Covered by Analysts at Evercore ISI
www.americanbankingnews.com - August 16 at 6:58 PM |
| Clovis (CLVS) Focuses on Label Expansion, Rubraca Impresses - Nasdaq
www.nasdaq.com - August 16 at 4:02 AM |
| Clovis Oncology, Inc. (CLVS) Insider Sells $210,150.00 in Stock
www.americanbankingnews.com - August 15 at 7:38 PM |
| Clovis (CLVS) Focuses on Label Expansion, Rubraca Impresses
finance.yahoo.com - August 15 at 5:58 PM |
| See what the IHS Markit Score report has to say about Clovis Oncology Inc.
finance.yahoo.com - August 11 at 5:43 PM |
| See what the IHS Markit Score report has to say about Clovis Oncology Inc.
finance.yahoo.com - August 11 at 5:43 PM |
| Clovis Oncology Enters Oversold Territory (CLVS) - Nasdaq
www.nasdaq.com - August 9 at 10:32 PM |
| A Biotech Binary Event Playbook: How To Play Clovis And Tesaro Ahead Of Label Decision - Benzinga
www.benzinga.com - August 9 at 3:07 AM |
| Insider Selling: Clovis Oncology, Inc. (CLVS) Director Sells 18,450 Shares of Stock
www.americanbankingnews.com - August 8 at 7:44 PM |
| Clovis Oncology, Inc. Expected to Post FY2018 Earnings of ($2.60) Per Share (CLVS)
www.americanbankingnews.com - August 7 at 9:30 AM |
| Zacks: Analysts Anticipate Clovis Oncology, Inc. (CLVS) Will Post Quarterly Sales of $18.58 Million
www.americanbankingnews.com - August 7 at 7:54 AM |
| Q3 2017 EPS Estimates for Clovis Oncology, Inc. Reduced by Oppenheimer Holdings (NASDAQ:CLVS)
www.americanbankingnews.com - August 7 at 7:09 AM |
Clovis Oncology (CLVS) Chart for Wednesday, September, 20, 2017
